Experimental design approach for Development of Carboplatin Loaded Chitosan Modified Liposomal formulation with Improved topical vaginal Therapeutic Potential.

One of the most prevalent cancers affecting women globally is cervical cancer. Cervical cancer is thought to cause 570.000 new cases annually, and standard treatments can have serious side effects. In this work main aim is to design, fabrication and evaluation of carboplatin loaded chitosan coated liposomal formulation (CCLF-I) for vaginal delivery in treatment of cervical cancer. The particle size and polydispersity index of the CCLF-1 was observed 269.33 ± 1.15 nm and 0.40 ± 0.002 nm, respectively. The in vitro mucin binding studies showed good adhesiveness of CCLF-I as compare to plain liposomes (CPLF-I), which was found 23.49% and 10.80%, respectively. The ex-vivo percent drug permeation from plain liposomal formulation (CPLF-I) was found to be higher in compare to chitosan coated liposomal formulation which was 56.33% while in CCLF-I it was observed 47.32% this is due to, higher retainability of delivery system (CCLF-I) on targeted site attained by coating of mucoadhesive polymer on liposomes. Ex vivo tissue retention studies exhibited 24.2% of CCLF-I in comparison to 10.34% from plain drug formulation (CPLF-I). The in vivo vaginal retention studies exhibited 14% of drug retention after 24 hours from novel formulation in comparison to 6% from plain formulation. The developed CCLF-I formulation would open a new avenue in the cervical treatment.